Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis

NCT01593332 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

44

Enrollment

OTHER

Sponsor class

Conditions

DMARD Resistant Rheumatoid Arthritis

Interventions

DRUG: Rituximab
DRUG: Rituximab

Sponsor

Mashhad University of Medical Sciences

Collaborators

[object Object]